Most of the currently used adjuncts that modulate wound healing target the fibroblast activity with antimetabolites and are effective in limiting the scarring process. However, these are associated with an increased incidence of adverse effects including chronic hypotony with maculopathy, cystic avascular blebs, bleb leakage, bleb infections, and endophthalmiltis. Blocking vascular endothelial growth factor (VEGF) can be a strong wound-modulating agent that is of potential use as an adjunct in glaucoma filtration surgery. In our study, we compared the efficacy and safety of adjuvant subconjunctival bevacizumab versus mitomycin C in subscleral trabeculectomy for patients having primary glaucoma with low to intermediate risk factors for bleb failure during a follow up period of 6 months as regards to IOP control, bleb morphology, complications and outcome.